Shangrao

Researchers are conducting a phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and effectiveness of HSK31858 in people with non-cystic fibrosis bronchiectasis (NCFBE). This condition is characterized by chronic cough, sputum production, and sometimes shortness of breath or respiratory failure, and the study focuses on reducing pulmonary exacerbations in these patients. Participants will receive either HSK31858 tablets, a new drug developed to inhibit DPP1 and potentially reduce lung flare-ups, or a placebo. The treatment will last 52 weeks, during which the frequency of pulmonary exacerbations will be closely monitored to compare results between the two groups. Throughout the study, participants will be involved in regular assessments to monitor their lung health and safety, including clinical evaluations and tracking of exacerbation events. The study aims to gather detailed information on how often lung flare-ups happen over the year-long treatment period to determine the drug's impact and safety profile.

Researchers are studying the effects of normobaric oxygen (NBO) therapy on patients who have experienced an acute ischemic stroke (AIS) and are transferred for endovascular thrombectomy (EVT). The goal is to assess the safety and effectiveness of NBO in improving functional outcomes three months after stroke. Stroke is a major cause of death and disability worldwide, and while treatments like mechanical thrombectomy can improve blood flow, less than half of patients with large vessel occlusion achieve good recovery. NBO offers potential brain protection by improving oxygen delivery to affected areas and reducing damage through multiple mechanisms. Participants will receive either inhaled 100% oxygen (NBO) or best medical care without NBO. The study focuses on patients transferred for EVT who meet specific stroke severity and imaging criteria. NBO treatment is delivered through oxygen inhalation, aiming to increase oxygen availability to the brain before reperfusion. The study is conducted in a Phase 3 setting and compares outcomes between those receiving NBO and those receiving standard care. During the study, participants will be monitored for disability levels using the modified Rankin scale at 90 days and one year after treatment. Assessments include neurological exams and imaging to confirm stroke details and severity. Researchers will also track safety and functional outcomes to evaluate the impact of NBO therapy. Participants are followed for at least three months after randomization to observe recovery and potential benefits.